ClearPoint NeuroCLPT
CLPT
About: ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
Employees: 115
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
1,361% more call options, than puts
Call options by funds: $7.09M | Put options by funds: $485K
100% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 11
53% more capital invested
Capital invested by funds: $76.6M [Q3] → $117M (+$40.3M) [Q4]
33% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 18
14% more funds holding
Funds holding: 78 [Q3] → 89 (+11) [Q4]
2.8% more ownership
Funds ownership: 24.76% [Q3] → 27.56% (+2.8%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
53%
upside
Avg. target
$25
92%
upside
High target
$30
130%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Stifel Mathew Blackman 24% 1-year accuracy 4 / 17 met price target | 92%upside $25 | Buy Maintained | 1 Apr 2025 |
B. Riley Securities Neil Chatterji 50% 1-year accuracy 1 / 2 met price target | 53%upside $20 | Buy Maintained | 28 Jan 2025 |
Lake Street Frank Takkinen 41% 1-year accuracy 9 / 22 met price target | 130%upside $30 | Buy Maintained | 21 Jan 2025 |
Financial journalist opinion
Positive
Seeking Alpha
1 month ago
ClearPoint Neuro: Drug Delivery Prospects Continue To Strengthen
ClearPoint's Q4 results were soft, although lumpy growth should be expected given the nature of ClearPoint's business. Neurosurgery growth remains robust, and the expansion of preclinical and clinical services should provide the drug delivery business with a boost within the next 18 months. ClearPoint also continues to control its cash burn, despite continuing to make investments in future growth.
Neutral
Seeking Alpha
1 month ago
ClearPoint Neuro, Inc. (CLPT) Q4 2024 Earnings Call Transcript
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Anderson Schock - B. Riley Securities Operator Greetings.
Negative
Zacks Investment Research
1 month ago
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Misses Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.19 per share a year ago.
Neutral
Accesswire
1 month ago
ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results
Achieved Record Revenue for 2024 and Growth of 31%; Reduced 2024 Operational Cash Burn by 35% SOLANA BEACH, CALIFORNIA / ACCESS Newswire / February 26, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its fourth quarter and full-year ended December 31, 2024. 2024 Full Year and Fourth Quarter Highlights Reported fourth quarter 2024 revenue of $7.8 million, a 14% year-over-year increase compared with the fourth quarter of 2023; Reported revenue of $31.4 million for the full year 2024, an increase of 31% over 2023 and representing the tenth consecutive year of growth; Overall product revenue, including biologics and drug delivery, grew 76% to $18.6 million for the full year as a result of the SmartFrame OR™ platform and ClearPoint Prism® Laser Therapy System and partner progression in clinical trials; Activated six new global centers in the fourth quarter for a total of 25 new centers in 2024, approximately three times our historic activation rate; Continued patient enrollment in numerous cell and gene therapy trials for partners selected in FDA expedited review programs across multiple indications; Full early repayment of the principal amount and interest on a $10 million convertible note leaving the Company with no outstanding debt; Quarterly operational cash burn of $1.2 million, bringing total 2024 operational cash burn of $9.0 million, a reduction of 35% versus 2023; and Reported cash and cash equivalents totaling $20.1 million as of December 31, 2024.
Neutral
Accesswire
1 month ago
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025
SOLANA BEACH, CA / ACCESS Newswire / February 14, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 fourth quarter and full year on Wednesday, February 26th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 fourth quarter and full year results on Wednesday, February 26th, at 4:30 p.m.
Neutral
Accesswire
1 month ago
ClearPoint Neuro Announces EU MDR Certification for the SmartFlow Cannula
SOLANA BEACH, CA / ACCESS Newswire / February 12, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced receipt of European Medical Device Regulation (EU MDR) approval for the SmartFlow Neuro Cannula. The SmartFlow Cannula was previously cleared under the Medical Device Directive 93/42/EEC (MDD) and has now successfully achieved the more rigorous EU MDR certification well ahead of the 2027 deadline for Class III devices.
Positive
Zacks Investment Research
2 months ago
CLPT Stock Gains on FDA Clearance for Navigation Software Version 3.0
ClearPoint achieves FDA 510(k) clearance for its Navigation Software Version 3.0, designed to standardize cell and gene therapy delivery in the United States.
Neutral
Accesswire
2 months ago
ClearPoint Neuro Announces FDA Clearance for ClearPoint Navigation Software Version 3.0
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 27, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received 510(k) clearance for its ClearPoint Navigation Software Version 3.0. "As we prepare for the wave of new patients that will be treated with cell and gene therapies in the years ahead, it is crucial that ClearPoint helps healthcare providers be ready by providing simplified workflows, offering solutions to increase surgical capacity and expanding access to our hardware and software," commented Joe Burnett, President and CEO at ClearPoint Neuro.
Positive
Zacks Investment Research
2 months ago
ClearPoint Neuro (CLPT) Surges 22.5%: Is This an Indication of Further Gains?
ClearPoint Neuro (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Positive
Zacks Investment Research
3 months ago
4 MedTech Stocks That Gained More Than 100% in 2024 With Room to Run
Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains.
Charts implemented using Lightweight Charts™